CTRI/2020/07/026539已完成4 期
A prospective, multi-centric, open-label, single-arm, phase 4 study to evaluate the safety and efficacy of canagliflozin plus metformin hydrochloride IR fixed-dose combination as an adjunct to diet and exercise to improve glycemic control in Indian adult patients with type 2 diabetes mellitus when treatment with both canagliflozin and metformin is appropriate
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 276
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Participant willing to adhere to diet and exercise regimen as recommended by the investigator
- •- Type 2 diabetes mellitus (T2DM) with inadequate glycemic control on diet and exercise, who in investigatorâ??s opinion are eligible to receive study drug as per prescribing information along with standard care for management of T2DM
- •- Women must be postmenopausal, defined as greater than 45 years of age with amenorrhea for at least 18 months, or greater 45 years of age with amenorrhea for at least 6 months and less than 18 months and a serum follicle stimulating hormone (FSH) level greater than 40 International Units Per Liter (IU/L), or surgically sterile (have had a hysterectomy or
- •bilateral oophorectomy, tubal occlusion), or otherwise be incapable of pregnancy, or sexually active and practicing a highly effective method of birth control, including hormonal prescription oral contraceptives, contraceptive injections, contraceptive patch, tubal ligation, intrauterine device, double-barrier method (example, condoms, diaphragm, or
- •cervical cap with spermicidal foam, cream, or gel), or male partner sterilization, and consistent with local regulations regarding use of birth control methods for participant participating in clinical studies, for the duration of their participation in the study, or not sexually active
- •- Women of childbearing potential, regardless of age must have a negative serum beta-human chorionic gonadotropin (beta-hCG) pregnancy test at screening and negative UPT at baseline (predose, Day 1)
- •- Treatment naive participants or participants on stable antihyperglycemic agent (AHA) therapy (for at least 12 weeks before screening) and have a screening visit Glycosylated Haemoglobin (HbA1c) of greater than or equal to 7.0 percent (%) and less than or equal to 10.0 %
排除标准
- •- History of liver or renal insufficiency (estimated creatinine clearance below 45 milliliter per minute [mL/min]); significant cardiac, vascular, pulmonary, gastrointestinal, endocrine, neurologic, hematologic, rheumatologic, psychiatric, or metabolic disturbances
- •- Known allergies, hypersensitivity, or intolerance to Canagliflozin, Metformin or Canagliflozin plus metformin hydrochloride immediate release (IR) Fixed Dose combination (FDC) or its excipients
- •- Use of any other sodium glucose cotransporter 2 (SGLT2) inhibitor (dapagliflozin or empagliflozin) within 12 weeks before the screening visit
- •- If female, the participant is pregnant or lactating or intending to become pregnant before, during, or within 30 days after last dose of study medication; or intending to donate ova during such time period
- •- History of diabetic ketoacidosis, type 1 diabetes mellitus (T1DM), pancreas or betaâ??cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
研究者
相似试验
已完成
2 期
A clinical trial to study the effects of ZYH1 in patients with high triglyceride levels in HIV associated lipodystrophy. .[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VII)].CTRI/2010/091/000107Cadila Healthcare Limited50
已完成
2 期
A clinical trial to study the effects of 4 mg ZYH1 in patients with Non alcoholic steatohepatitis (NASH)..[Prospective Randomised Efficacy and Safety of Saroglitazar (PRESS VIII)].CTRI/2010/091/000108Cadila Healthcare Limited30
招募中
4 期
A clinical study to evaluate the efficacy and safety of Levonorgestrel Intrauterine System (Emily) in Indian womenwith Dysfunctional Uterine BleedingCTRI/2012/07/002843HLL Lifecare Limited75
招募中
不适用
Indian Human Insulin Registry (INHIRIT)CTRI/2017/10/010298Biocon Limited
招募中
1 期
A phase I study to evaluate the safety of GBL1204 in patients with neovascular age-related macular degeneratioCTRI/2024/02/063012Gennova Biopharmaceuticals Limited